Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906908 | 1.00 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL23971247 | 1.00 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL19635138 | 0.98 | CA14 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL4907545 | 0.93 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL25720861 | 0.85 | ALDH1A1 (0.42) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL2682850 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL28996647 | 0.85 | CA14 (0.46) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL100090 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL9050850 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL14098625 | 0.84 | EPHX2 (0.41) | HDAC6HDAC1HDAC2CA14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153028-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 深圳晶蛋生物医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-109715632-B | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| CN-109715632-A | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | HDAC6 711/4885HDAC1 712/4885HDAC2 1137/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | HDAC6 711/4885HDAC1 712/4885HDAC2 1137/4885 |
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | HDAC6 2000/4885HDAC1 883/4885HDAC2 1012/4885 |
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | HDAC6 1577/4885HDAC1 710/4885HDAC2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.